Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | UBE2N | P61088 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | HTR6 | P50406 | 7/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29402217 | 1.00 | KDM4E (0.68) | KDM4EUBE2NL3MBTL1HTR6ALOX5 | |
| SCHEMBL819444 | 0.90 | LMNA (0.62) | KDM4EUBE2NL3MBTL1HTR6LMNA | |
| SCHEMBL29737165 | 0.90 | LMNA (0.62) | KDM4EUBE2NL3MBTL1HTR6LMNA | |
| SCHEMBL17394583 | 0.87 | HTR6 (0.57) | KDM4EUBE2NL3MBTL1HTR6LMNA | |
| SCHEMBL4014002 | 0.87 | HTR6 (0.60) | KDM4EUBE2NL3MBTL1HTR6ALOX5 | |
| SCHEMBL15757279 | 0.85 | HTR6 (0.59) | KDM4EUBE2NL3MBTL1HTR6LMNA | |
| SCHEMBL4012220 | 0.85 | HTR6 (0.61) | KDM4EUBE2NHTR6LMNASMN1; SMN2 | |
| SCHEMBL3615171 | 0.82 | HTR6 (0.78) | KDM4EUBE2NL3MBTL1HTR6ALOX5 | |
| SCHEMBL31092832 | 0.82 | HTR6 (0.58) | KDM4EUBE2NL3MBTL1HTR6ALOX5 | |
| SCHEMBL14637084 | 0.81 | PTGDR2 (0.49) | KDM4EUBE2NL3MBTL1HTR6ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108774122-B | Method for synthesizing diaryl ketone compound by carbonylation taking chloroform as carbonyl source without participation of transition metal | 南京师范大学 | 2021-06-11 | — | — | CN | disclosed |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2020-04-28 | — | — | US | disclosed |
| US-10174029-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2019-01-08 | — | — | US | disclosed |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2019-01-03 | — | — | US | disclosed |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-09-04 | — | — | US | disclosed |
| US-20180170929-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-06-21 | — | — | US | disclosed |
| US-20180170929-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-06-21 | — | — | US | disclosed |
| US-9944640-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-04-17 | — | — | US | disclosed |
| US-9944640-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-04-17 | — | — | US | disclosed |
| US-20170217961-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-08-03 | — | — | US | disclosed |
| EP-1147107-A4 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO INC (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1147107-A1 | NOVEL ANGIOGENESIS INHIBITORS | Merck & Co., Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6265403-B1 | TYROSINE INHIBITORS | MERCK & CO., INC. | 2001-07-24 | — | — | US | disclosed |
| EP-0888339-A4 | SYNTHESIS OF INDOLYLMALEIMIDES | LILLY CO ELI (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-2000043393-A1 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO., INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| US-6037475-A | REACTING OPTIONALLY SUBSTITUTED, N-PROTECTED INDOL-3-YL-ACETAMIDE WITH AN ALKYL OXALATE AND A STRONG ORGANIC BASE IN A POLAR APROTIC SOLVENT FORMING OPTIONALLY SUBSTITUTED 4-(INDOL-3-YL)-3-HYDROXY PYRROLE-2,5-DIONE | ELI LILLY & COMPANY (US) | 2000-03-14 | — | — | US | disclosed |
| US-5919946-A | REACTING AN ACTIVATED MALEIMIDE WITH AN ORGANOMETALLIC-3-INDOLE IN PRESENCE OF A PALLADIUM TRANSITION METAL CATALYST | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5859261-A | PROTEIN KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0888339-A1 | SYNTHESIS OF INDOLYLMALEIMIDES | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034890-A1 | SYNTHESIS OF INDOLYLMALEIMIDES | ELI LILLY AND COMPANY (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170929-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | DPYD, MTHFD1, TYMS | KDM4E 2454/4885UBE2N 4676/4885L3MBTL1 2508/4885 |
| US-20170217961-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | DPYD, MTHFD1, TYMS | KDM4E 2454/4885UBE2N 4676/4885L3MBTL1 2508/4885 |
| US-10174029-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | DPYD, MTHFD1, TYMS | KDM4E 2454/4885UBE2N 4676/4885L3MBTL1 2508/4885 |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | MTHFD1, MTHFD2, TPMT | KDM4E 3971/4885UBE2N 4219/4885L3MBTL1 3507/4885 |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | KDM4E 3971/4885UBE2N 4219/4885L3MBTL1 3507/4885 |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | KDM4E 3971/4885UBE2N 4219/4885L3MBTL1 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.